A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

NCT04732221 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension
Hypertension, Pulmonary

Interventions

DRUG: Frespaciguat
DRUG: Placebo to Frespaciguat

Sponsor

Merck Sharp & Dohme LLC